Medical Affairs Reputations: Melanoma (EU5)
Top marks from oncologists show medical affairs push is paying off for immunotherapies
In the EU5 Melanoma treatment market, one brand’s medical affairs team is reaching more oncologists—and earning significantly higher overall quality scores—than any other team.
But are they delivering all of the services oncologists want? Find out in Medical Affairs Reputations: Melanoma.
Comparing teams for 8 major melanoma drugs head to head, the report reveals how oncologists rate them overall, and on 12 key medical affairs services including:
- Providing information
- Responding to medical inquiries
- Enhancing patient care
- Supporting clinical trials, and more
Understand where the top medical affairs teams lead and lag, so you can build a winning competitive strategy for your team.Reasons to Purchase
Answering Key Questions about Medical Affairs Teams for 8 Major Melanoma Drugs
- Imlygic (talimogene laherparepvec; Amgen): For which 3 services does Imlygic’s team earn the lowest satisfaction scores?
- Keytruda (pembrolizumab; Merck Sharpe & Dohme.): Is Keytruda’s team better at providing relevant materials or information about clinical trials?
- Mekinist (trametinib; Novartis): Which team earns higher satisfaction scores for promptly responding to medical inquiries, Mekinist’s, Tafinlar’s or Yervoy’s?
- Opdivo (nivolumab; BMS): Opdivo’s team’s performance is neck and neck with Keytruda’s for three services. What are they?
- Proleukin (aldesleukin; Novartis): Proleukin’s team and Imlygic’s team are almost equally active. Which one earns the higher overall quality score?
- Tafinlar (dabrafenib; Novartis): Tafinlar’s team needs to improve 2 medical affairs services. How important are those services to oncologists?
- Yervoy (ipilimumab; BMS): Is Yervoy’s team better at supporting clinical trials or providing unbiased competitive information?
- Zelboraf (vemurafenib; Roche): In which area does Zelboraf’s team earn higher satisfaction scores than Opdivo’s?
- One team is way ahead: Rated for overall quality of interactions, the leading team scores one and a half times as high as its nearest rival.
- Timely information is key: Oncologists rely on medical affairs teams to keep them up to date, and to provide actionable information directly related to treatment decisions.
- Moderate satisfaction despite uneven performance: Although performance scores for specific services vary from team to team, satisfaction scores are moderately high.
- Specific improvements needed: All but two teams need to work on one or two medical services to improve their satisfaction scores. Find out how important those services are to oncologists.
- Face-to-face communication preferred: Find out the best venues for medical affairs teams to meet with oncologist, and learn how receptive they are to electronic communications.
- More frequent interactions wanted: Does that mean once a quarter? Once a month? Once a week? See how often your team should reach out to oncologists.
- Call for an attitude adjustment: Nearly 30% of oncologists surveyed say teams’ medical affairs attitude needs specific improvements. Find out what they are.
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
Does your medical affairs team deliver?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
What needs improvement?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
Based on Interviews with Practicing Oncologists
We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK), chosen from the largest community of validated physicians in the world.
- Have been practicing for between 3 and 35 years
- See at least 5 patients with Melanoma in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
We conducted the survey between June 8th and 13th, 2016.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed. About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.